Tipranavir is a Medicine belongs to Antiviral group whose information about Brand can be referenced from   Book : Martindale    Page : 1006   Edition : 37  

  ►   Brandname : Aptivus
  ►  Strength : Capsule with 250 mg. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 889   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 1006   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 HIV infection and AIDS Oral 500 mg Capsule b.d. Dose: with ritonavir 200 mg given with food

Ref :-  Book : Martindale    Page : 1006   Edition : 37  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 HIV infection and AIDS 2 Year Oral 14 mg/kg Capsule

Ref :- Book : Martindale    Page : 1006   Edition : 37  
►  Side Effect : Gastrointestinal disturbances, Abdominal pain, Diarrhoea, Dyspepsia, Flatulence, Nausea, Vomiting, Anorexia, Fatigue, Headache, Increased risk of bleeding, Hyperlipidaemia, Hypertriglyceridaemia, Severe hepatotoxicity, Intracranial haemorrhage including some fatalities, Rashes, Immune reconstitution syndrome, Lipodystrophy, central obesity, Buffalo hump, Peripheral wasting, Facial wasting, breast enlargement, Cushingoid appearance, Hypercholesterolaemia, Insulin resistance, Hyperglycaemia, Hyperlactataemia
Ref :-   Book : Martindale    Page : 1005   Edition : 37.  

►  Drug Interaction : Drug interaction of Tipranavir is with ,  Alfuzosin , Amiodarone , Bepridil, Metoprolol , Propafenone, Quinidine , Astemizole, Terfenadine, Dihydroergotamine, Ergometrine , Ergotamine, Methylergometrine, Cisapride , Pimozide , Midazolam , Triazolam , Simvastatin , Lovastatin
Ref :-   Book : Martindale    Page : 1005   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Tipranavir is both an inducer and an inhibitor of the cytochrome P450 isoenzyme CYP3A4. Ritonavir boosted Tipranavir is contra-indicated with drugs that are highly dependent on CYP3A4 or CYP2D6 for clearance and for which elevated plasma concentrations are associated with serious or life-threatening events. These drugs include alpha 1 adreno receptors agonist alfuzosin, antiarrhythmics (amiodarone, bepridil, flecainide, metoprolol, propafenone, and quinidine), antihistamines (astemizole and terfenadine), ergot derivatives (dihydroergotamine, ergometrine, ergotamine, and methylergometrine), gastrointestinal prokinetics (cisapride), antipsychotics (pimozide), sedatives and hypnotics (midazolam and triazolam), and statins (simvastatin and lovastatin).
Ref :-   Book : Martindale    Page : 1005   Edition : 37.  

►  Contraindication : Hepatic impairment, Patients should be closely monitored for clinical signs and symptoms of hepatitis; monitoring of liver enzymes is recommended before and during treatment with tipranavir., Treatment should be interrupted or stopped if liver function deteriorates and should be permanently stopped in those patients with liver enzyme values more than 10 times the upper limit of normal or in those who develop signs or symptoms of clinical hepatitis., Caution is advised in treating patients who are at increased risk of bleeding such as those with haemophilia A and B or who are taking antiplatelet drugs or anticoagulants as reports of spontaneous bleeding have been associated with the use of HIV-protease inhibitors
Ref :-   Book : Martindale    Page : 1005   Edition : 37.  
  ►  Mechanism of Action :   Tipranavir is a non-peptide HIV-protease inhibitor. It interferes with the formation of essential viral proteins making them incapable of infecting other cells. HIV isolates resistant to tipranavir have been reported and viral resistance develops rapidly when HIV-protease inhibitors are given alone and therefore they are used with other antiretrovirals. Various degrees of cross-resistance between HIV-protease inhibitors may occur.
Ref :-   Book : Martindale    Page : 1005   Edition : 37.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA

DIETARY Substance Interactions

​   ► This Medicine interact with :- NA

ContraIndication DIETARY Substance

​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   Faecal
Ref :-   Book : Martindale    Page : 1005   Edition : 37.  

►    Plasma Half-life :   Min value :-   4.8 hours ,    Max value :-   6 hours .  
Ref :-   Book : Martindale    Page : 1005   Edition : 37.  

►    Peak Plasma Concentration :   Min value :-   1 hours,    Max value :-   5 hours.  
Ref :-   Book : Martindale    Page : 1005   Edition : 37.